Rebecca Godfrey

COO , ExpressionEdits

Dr Rebecca Godfrey is the COO at ExpressionEdits, a Cambridge-based biotechnology company optimizing protein expression using AI and proprietary intronization technology. At ExpressionEdits Rebecca provides leadership and strategic direction to all business, financial and operational aspects of the organisation, leading on all commercial partnership activities.

Rebecca’s extensive track record of building highly successful organizations, teams, and systems, covers all stages of the product lifecycle, across a wide variety of therapeutic modalities and in all regions worldwide, including emerging markets. Rebecca has held Director level roles at Eisai and AbbVie and the role of Global Head Regional PV Excellence at Roche. Rebecca’s most recent roles include COO at healthtech start-up, OKKO Health, and Research Chief of Staff for the clinical-stage gene therapy biotech, Freeline Therapeutics (now Spur Therapeutics).

Rebecca also serves as Chair of the Board of Teens Unite fighting cancer and is author of the best-selling book ‘The Leadership Vaccine: Drive innovation, increase efficiency and build resilience in highly regulated industries’.

 

Carolyn Porter

Chief Executive Officer, Outrun Therapeutics

Carolyn has over 25 years’ experience in career spanning roles in biotech and pharmaceutical companies, technology transfer and academia, and is currently CEO of Outrun Therapeutics, a spin out of the University of Dundee.  She has held Board roles including CEO and NED roles in 7 biotech companies developing novel therapies across multiple indications including in oncology and neurology.  She is also currently a NED representing Innovate UK on the Board of the Cell & Gene Therapy Catapult.  Organisations she has previously worked for include Novartis, Chiron, Oxford University and Ernst & Young.  Carolyn has a PhD in Immunology, BSC in Pharmacology and an MBA.

Özgür Tuncer

CEO & Executive Director, Stablepharma Ltd

Özgür has over two decades of experience in the biopharmaceutical industry with deep expertise in executive leadership, strategy, M&A and investments. In addition to being the CEO & Executive Director of Stablepharma, Özgür is an investment partner with Ascension Ventures and co-founder of the Ascension Life Fund. In that capacity, he is involved at board-level in early-stage healthcare and life sciences companies in the UK.

Özgür in a Non-Executive Director at Cambridge-based precision cancer company TailorBio and fertility company ExSeed Health, as well as being a Board Advisor to Pangaea Data. Most recently, he was Global Vice President in IQVIA, leading company’s Financial Investors practice. In that role, Özgür was involved in more than 300 industry-shaping transactions with valuations of $100m-10bn+, working with world’s leading Private Equity & Venture Capital investors.

Özgür spent over 6 years in USA working for Pfizer in New York and Pharmacia in New Jersey before moving into management consultancy. In Pfizer, he was in charge of portfolio strategy and investments in infectious diseases globally. During that time, he was deeply involved in developing anti-viral and anti-bacterial products. Furthermore, Özgür was part of a small strategy task force who led Pfizer’s entry into vaccine space, acquiring PowderMed in 2006, a UK vaccine company.

Prior to joining IMS Health (IQVIA), Özgür was the founding Managing Partner of SARGA Associates with offices in New Jersey, USA and London, UK. He has also worked with several NGOs including Medicines for Malaria Venture (MMV) in Geneva, UNITAID, Clinton Foundation/Clinton Health Access Initiative and the Gates Foundation.

Özgür has lived and worked in the UK, USA, France and Turkey. He holds an MSc in Management Sciences from the London School of Economics and a BSc in Business Administration from the Middle East Technical University (Turkey).